Ayala Pharmaceuticals (NASDAQ:ADXS) Now Covered by StockNews.com

StockNews.com began coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research report released on Monday morning. The brokerage issued a sell rating on the stock.

Ayala Pharmaceuticals Trading Down 10.0 %

Shares of ADXS opened at $0.03 on Monday. The firm has a market capitalization of $1.15 million, a price-to-earnings ratio of 0.00 and a beta of 1.62. The firm’s fifty day simple moving average is $0.04 and its 200-day simple moving average is $0.05. Ayala Pharmaceuticals has a twelve month low of $0.00 and a twelve month high of $1.49.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.